ReviewMedChemComm2017
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents.
Review in MedChemComm, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.Molecules (Basel, Switzerland) · 2020Pooled it
- Synthesis of Quinazoline Derivatives and Mechanistic Approaches in Lung and Breast Cancers.Molecules (Basel, Switzerland) · 2026Article
- Nature-Inspired Gold(I) Complexes as Anticancer Agents: Ligand Design, Structure-Activity Relationships, and Mechanisms.Cancers · 2026Review
- Advances in quercetin-based therapeutics for breast cancer: natural, synthetic, and nanotechnology-driven approaches.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Development of substituted 2-(4-(sulfonyl)piperazin-1-yl)quinazoline molecular hybrids as a new class of antimalarials.RSC advances · 2025Article
- Multi-Kinase Inhibition by New Quinazoline-Isatin Hybrids: Design, Synthesis, Biological Evaluation and Mechanistic Studies.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Quinazolines [Molecules (Basel, Switzerland) · 2025Review
- Design, antiproliferative potency, and in silico studies of novel 5-methylfuran-3-yl)thio)-3-phenylquinazolin-4(3H)-one based derivatives as potential EGFR inhibitors.Scientific reports · 2025Article
- Anticancer, antimicrobial and molecular docking analysis of newly synthesized iodoquinazoline derivatives.AMB Express · 2025Article
- Unveiling the role of Ndrg1 gene on the oxidative stress induction behind the anticancer potential of styrylquinazoline derivatives.Scientific reports · 2025Article
- Design, Synthesis, and Biophysical Characterization of Pyridine Bis-Quinazoline Derivatives as Selective G-Quadruplex DNA Stabilizers.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Designing molecular hybrids as novel breast cancer therapeutics.Future medicinal chemistry · 2025Article
- Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- The impact of 9-azaglycophymine and phenylguanidine derivatives on the proliferation of various breast cancer cell lines in vitro and in vivo.Scientific reports · 2024Article
- Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy.Cancers · 2024Review
- New pyridopyrimidine derivatives as dual EGFR and CDK4/cyclin D1 inhibitors: synthesis, biological screening and molecular modeling.Future medicinal chemistry · 2024Article
- Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update.RSC medicinal chemistry · 2024Review
- Cancer research in the United Arab Emirates from birth to present: A bibliometric analysis.Heliyon · 2024Article
- Design, Synthesis, Pharmacological Evaluation of Quinazolin-4(3Drug design, development and therapy · 2024Article
- Novel N-(3-ethynyl Phenyl)-6,7-bis(2-methoxyethoxy)Quinazoline-4-amine Derivatives: Synthesis, Characterization, Anti-cancer Activity,Anti-cancer agents in medicinal chemistry · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the major causes of worldwide human mortality. A wide range of cytotoxic drugs are available on the market, and several compounds are in different phases of clinical trials. Many studies suggest that these cytotoxic molecules are also associated with different types of adverse side effects; therefore researchers around the globe are involved in the development of more efficient and safer anticancer drugs. In recent years, quinazoline and its derivatives have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors. The aim of this article is to comprehensively review and highlight the recent developments concerning the anticancer activity of quinazoline derivatives as well as offer perspectives on the development of novel quinazoline derivatives as anticancer agents in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.